Wellington Management Group LLP Has $639,000 Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Wellington Management Group LLP lowered its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 3.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 179,612 shares of the company’s stock after selling 5,579 shares during the quarter. Wellington Management Group LLP owned approximately 0.20% of Aquestive Therapeutics worth $639,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. New York State Common Retirement Fund raised its holdings in shares of Aquestive Therapeutics by 713.3% in the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock valued at $43,000 after purchasing an additional 10,700 shares during the period. PKS Advisory Services LLC acquired a new position in Aquestive Therapeutics during the fourth quarter worth approximately $63,000. China Universal Asset Management Co. Ltd. bought a new stake in Aquestive Therapeutics in the fourth quarter valued at approximately $69,000. BNP Paribas Financial Markets lifted its position in shares of Aquestive Therapeutics by 252.2% in the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock valued at $94,000 after buying an additional 13,481 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of Aquestive Therapeutics during the 4th quarter worth approximately $115,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on AQST shares. Lake Street Capital cut their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 7th. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a report on Friday, March 7th. Cantor Fitzgerald started coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price target on the stock. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Wednesday, April 2nd. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $10.67.

Aquestive Therapeutics Stock Up 2.0 %

Shares of Aquestive Therapeutics stock opened at $2.52 on Tuesday. The stock has a market capitalization of $249.15 million, a price-to-earnings ratio of -5.60 and a beta of 2.59. Aquestive Therapeutics, Inc. has a twelve month low of $2.20 and a twelve month high of $5.80. The company has a 50-day simple moving average of $2.88 and a two-hundred day simple moving average of $3.74.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $11.87 million for the quarter, compared to the consensus estimate of $13.11 million. On average, sell-side analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.